share_log

6-K: Novo Nordisk A/S - Share Repurchase Programme

6-K: Novo Nordisk A/S - Share Repurchase Programme

6-K:諾和諾德-股票回購計劃
美股SEC公告 ·  08/06 08:23

Moomoo AI 已提取核心訊息

Novo Nordisk A/S, a leading global healthcare company, has successfully concluded its share repurchase program initiated on May 6, 2024. The program, which was part of a larger DKK 20 billion buyback plan set to occur over a 12-month period starting February 6, 2024, aimed to repurchase B shares for up to DKK 2.2 billion between May 7 and August 5, 2024. As of the end date, the company has repurchased a total of 2,332,876 B shares at an average price of DKK 878.97, amounting to a transaction value of DKK 9,727,706,050. Following the completion of this phase, Novo Nordisk now holds 12,432,916 B shares as treasury shares, representing 0.3% of the share capital. The company's total share count, including treasury shares, stands at 4,465,000,000 A and B shares. Novo Nordisk's shares are traded on Nasdaq Copenhagen and its ADRs on the New York Stock Exchange. The company, founded in 1923 and headquartered in Denmark, is committed to defeating serious chronic diseases and employs approximately 66,000 people worldwide.
Novo Nordisk A/S, a leading global healthcare company, has successfully concluded its share repurchase program initiated on May 6, 2024. The program, which was part of a larger DKK 20 billion buyback plan set to occur over a 12-month period starting February 6, 2024, aimed to repurchase B shares for up to DKK 2.2 billion between May 7 and August 5, 2024. As of the end date, the company has repurchased a total of 2,332,876 B shares at an average price of DKK 878.97, amounting to a transaction value of DKK 9,727,706,050. Following the completion of this phase, Novo Nordisk now holds 12,432,916 B shares as treasury shares, representing 0.3% of the share capital. The company's total share count, including treasury shares, stands at 4,465,000,000 A and B shares. Novo Nordisk's shares are traded on Nasdaq Copenhagen and its ADRs on the New York Stock Exchange. The company, founded in 1923 and headquartered in Denmark, is committed to defeating serious chronic diseases and employs approximately 66,000 people worldwide.
一家領先的全球醫療保健公司——諾和諾德A/S已經成功完成了於2024年5月6日啓動的股票回購計劃。該計劃是大型200億丹麥克朗回購計劃的一部分,計劃在2024年2月6日開始的12個月內進行,旨在在2024年5月7日至8月5日期間回購最多22億丹麥克朗的b類股份。截至結束日期,公司已回購23328760億股股票,平均價格爲878.97丹麥克朗,交易金額爲97,277,060,500丹麥克朗。完成此階段後,諾和諾德現持有124329160億股庫藏股,佔公司股本的0.3%。其總股本,包括庫藏股,爲44.65億A類和b類股份。諾和諾德的股票在納斯達克哥本哈根交易,並且其American Depositary Receipts在紐約證券交易所上市。這家成立於1923年、總部位於丹麥的公司致力於戰勝嚴重的慢性疾病,全球擁有約66,000名員工。
一家領先的全球醫療保健公司——諾和諾德A/S已經成功完成了於2024年5月6日啓動的股票回購計劃。該計劃是大型200億丹麥克朗回購計劃的一部分,計劃在2024年2月6日開始的12個月內進行,旨在在2024年5月7日至8月5日期間回購最多22億丹麥克朗的b類股份。截至結束日期,公司已回購23328760億股股票,平均價格爲878.97丹麥克朗,交易金額爲97,277,060,500丹麥克朗。完成此階段後,諾和諾德現持有124329160億股庫藏股,佔公司股本的0.3%。其總股本,包括庫藏股,爲44.65億A類和b類股份。諾和諾德的股票在納斯達克哥本哈根交易,並且其American Depositary Receipts在紐約證券交易所上市。這家成立於1923年、總部位於丹麥的公司致力於戰勝嚴重的慢性疾病,全球擁有約66,000名員工。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息